Fig. 4: Comparative analysis of LAG-3+ and PD-1+ CD8 and CD4 T cells in metastatic and adjuvant treatment of melanoma. | Nature Medicine

Fig. 4: Comparative analysis of LAG-3+ and PD-1+ CD8 and CD4 T cells in metastatic and adjuvant treatment of melanoma.

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

Fig. 4

a, Baseline PD-1+, LAG-3+ and PD-1+LAG3+ CD8 cells in tumor and blood in advanced melanoma (RELATIVITY-047). b, Baseline expression of PD-1+, LAG-3+ and PD-1+LAG-3+ CD8 and CD4 cells in blood in advanced melanoma (RELATIVITY-047) and adjuvant-treated melanoma (RELATIVITY-098). c, Delta change of baseline to on-treatment expression of PD-1+, LAG-3+ and PD-1+LAG-3+ CD8 and CD4 cells in blood in advanced and adjuvant-treated melanoma. a, Tumor CD8 frequencies from CODEX/PhenoCycler. Blood frequencies from multiparametric flow cytometry. b, Figure is non-log mean and non-log median, and n is the number of patients with flow cytometry. Figure is the log-transformed frequencies of each population. c, Figure is non-log mean of delta and non-log median of delta, and n is the number of patients with flow cytometry. LAG-3+ and LAG-3+PD-1+ figures represent the log-transformed frequencies of each population. Statistical tests were two-sided Wilcoxon tests with no multiple comparisons. Error bars are s.e. of the estimated marginal means.

Back to article page